Ciphergen Biosystems and Salford Systems Announce Biomarker Patterns(TM) Software 5.0
April 05 2004 - 10:00AM
PR Newswire (US)
Ciphergen Biosystems and Salford Systems Announce Biomarker
Patterns(TM) Software 5.0 Multivariate Classification Software
Enables Discovery of Powerful Multi-protein Biomarker Patterns That
Translate to Assays With High Predictive Accuracy FREMONT, Calif.,
April 5 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. , in
conjunction with Salford Systems, announced today the release of
Biomarker Patterns(TM) Software 5.0, Ciphergen's latest advanced
offering for elucidation of clinically relevant protein patterns.
Recently, the United States Patent and Trademark Office issued a
patent to Ciphergen, directed to finding protein patterns in mass
spectrometry data using the classification and regression tree
algorithm to identifydiagnostic patterns of proteins derived from
any type of mass spectrometry data. This method is used in
Ciphergen's SELDI ProteinChip(R) Biomarker System for biomarker
discovery, validation and assay development. "Biomarker Patterns
Software is the only commercially available clinical proteomics
software that addresses both discovery of protein multi-markers and
their translation to assays with high predictive accuracy,"
commented Martin Verhoef, President of Ciphergen's Biosystems
Division. "This sets Ciphergen's proteomics platform apart from
groups that are using other pattern recognition methods without
protein ID and from groups cataloging protein ID's for literature
validation in order to guess which protein will make a good assay,
a classical approach which has had limited success in developing in
vitro diagnostic tests over the past decades." Biomarker Patterns
Software is a unique, Windows-based package for supervised
classification of SELDI (Surface-Enhanced Laser
Desorption/Ionization) mass spectral data sets derived from the
Ciphergen ProteinChip(R) platform. Ciphergen Biosystems and Salford
Systems collaborated to create BPS by modifying and enhancing
Salford's existing CART(R) technology. Salford's expertise in the
Classification and Regression Tree procedure, introduced by Leo
Breiman, Jerome Friedman, Richard Olshen and Charles Stone in 1984,
is well-established. Ciphergen has exclusive rights to this
software in the field of proteomics. A major new component of
Biomarker Patterns Software 5.0 allows intelligent feature
selection using functionality from Salford's TreeNet algorithm,
which embodies Jerome Friedman's MART (Multiple Additive Regression
Trees). The methodology is based on CART, but with adaptations
designed to extract the most reliable information from the data
set. TreeNet builds a large number of small trees, each designed to
help correct the errors of its predecessors. This new feature
avoids the potential problem of "overfitted data," a condition that
occurs when many data points are analyzed against a relatively
small sample set, a situation frequently encountered in the early
phases of a discovery project, when a relatively small number of
samples may be available. By allowing a more focused analysis on
the variables that really matter, there is a notable payoff from
pre-selecting variables. "Biomarker Patterns Software 5.0
incorporates a major analytical advance in which a boosting
algorithm such as TreeNet is used to identify the proteins that are
relevant to a particular disease and then CART is used to summarize
and display the results in a clear, concise, and scientifically
comprehensible manner," stated Dan Steinberg, President and CEO of
Salford Systems. "This is the first time these technologies have
been combined in this way and putting such a powerful but easy to
use software tool in the hands of a large universe of clinical
researchers and biologists holds the potential to discover and
create break-through, multi-biomarker diagnostic assays." About
Ciphergen Ciphergen's Biosystems Division develops, manufactures
and markets a family of ProteinChip(R) Systems and services for
clinical, research, and process proteomics applications, as well as
a broad range of bioseparations media for protein purification and
large scale production. ProteinChip Systems enable protein
discovery, characterization, identification and assay development
to provide researchers with predictive, multi-marker assay
capabilities and a better understanding of biological function at
the protein level. Ciphergen's Diagnostics Division is dedicated to
the discovery of protein biomarkers and panels of biomarkers and
their development into protein molecular diagnostic tests that
improve patient care; and to providing collaborative R&D
services through its Biomarker Discovery Center(R) laboratories for
biomarker discovery for new diagnostic tests as well as
pharmacoproteomic services for improved drug toxicology, efficacy
and theranostic assays. Additional information about Ciphergen can
be found at http://www.ciphergen.com/. About Salford Systems
Salford Systems, founded in 1983, provides state-of-the-art data
mining and business intelligence software and consultation
services. The award winning software is being successfully used in
all aspects of complex data analysis including predictive modeling
and segmentation, and is being applied to credit risk scoring,
targeted marketing, analytical Customer Relationship Management
(CRM), fraud and intrusiondetection, web site personalization, drug
discovery, and manufacturing quality control. Industries using
Salford Systems products and services include banking, financial
services, insurance, telecommunications, transportation,
pharmaceuticals, healthcare, manufacturing, law enforcement and
security, retail and catalog sales, and education. Salford Systems
software is installed at more than 4,500 sites worldwide, including
300 major universities. Safe Harbor Statement Note Regarding
Forward-Looking Statements: For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the use of ProteinChip
technology to accelerate the discovery of useful protein biomarkers
and the biological function of proteins within patterns of
biomarkers, develop and commercialize protein molecular diagnostics
that improve patient care, the ability to provide services that
lead to improved toxicology assays and diagnostic assays, the
expected benefits of using the new classification approach with
SELDI-MS, the expectation that protein multi-marker tests will have
a significant future role in diagnostics, prognostics, predictive
toxicology and drug development, and statements regarding our
Diagnostics Division. Actual results may differ materially from
those projected in such forward-looking statements due to various
factors, including, the ProteinChip technology's ability to
validate and/or develop these protein biomarkers as diagnostic or
toxicology assays, and the Company's ability to successfully
commercialize such tests, and our ability to protect and promote
our proprietary technologies. Investors should consult Ciphergen's
filings with the Securities and Exchange Commission, including its
Form 10-K dated March 15, 2004, for furtherinformation regarding
these and other risks of the Company's business. NOTE: Ciphergen,
ProteinChip and Biomarker Patterns are trademarks of Ciphergen
Biosystems, Inc. CART is a trademark of Salford Systems.
DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers,
Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024